# Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation

> **NCT01929200** · PHASE2 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Non-small-cell Lung Cancer

## Interventions

- **DRUG:** 1-year treatment with icotinib
- **DRUG:** 2-year treatment with icotinib

## Key facts

- **NCT ID:** NCT01929200
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-08
- **Primary completion:** 2015-12
- **Final completion:** 2017-08
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2015-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01929200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01929200, "Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01929200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*